Company intelligence / Profile preview

NanoSynex

Ownership: Private
Development stage: Preclinical

Overview

NanoSynex has developed a rapid phenotypic Antimicrobial Susceptibility Test using microfluidics to optimize bacterial growth and quickly match antibiotics to patient-specific infections. The technology aims to reduce time-to-result for AST from days to hours, improving targeted antibiotic use and combating antibiotic resistance. No clinical trial results are reported as it’s a diagnostic device/platform. The company was acquired in majority by Qualigen Therapeutics in May 2022.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMicrofluidic diagnostic platform (for Antimicrobial Susceptibility Testing)
Industry: Molecular Diagnostics

Partnerships

Qualigen Therapeutics (acquirer/collaborator)

Beyond the preview

Go deeper on NanoSynex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoSynex.

Explore the full profile